Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tom Crosby

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
BJS Open|May 22, 2026
Interhospital variations in practice and technical outcomes for endoscopic resection of early oesophagogastric adenocarcinoma: multicentre CONGRESS data set analysisKirsty Cole, Pradeep Bhandari, James A Gossage, et al.
Gut|March 29, 2024
National Institute for Health and Care Excellence (NICE) guidance on monitoring and management of Barrett's oesophagus and stage I oesophageal adenocarcinomaMassimiliano di Pietro, Nigel J Trudgill, Melina Vasileiou, et al.
European Journal of Cancer (Oxford, England : 1990)|March 25, 2017
NEOSCOPE: A randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinomaSomnath Mukherjee, Christopher Nicholas Hurt, Sarah Gwynne, et al.
BMC Cancer|April 17, 2015
NEOSCOPE: a randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinomaSomnath Mukherjee, Christopher N Hurt, Sarah Gwynne, et al.
Oncotarget|January 8, 2019
Genomic loss of heterozygosity and survival in the REAL3 trialElizabeth C Smyth, Catherine Cafferkey, Andrea Loehr, et al.
JAMA Oncology|June 21, 2019
Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma: A Randomized Phase 2 Clinical TrialElizabeth C Smyth, Samuel Rowley, Fay H Cafferty, et al.
The Lancet. Oncology|April 19, 2013
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trialTom Waddell, Ian Chau, David Cunningham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 5, 2024
Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III TrialDaniel H Palmer, Richard Jackson, Christoph Springfeld, et al.
Gut|November 17, 2020
EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancersElizabeth C Smyth, Georgios Vlachogiannis, Somaieh Hedayat, et al.
Lancet (London, England)|January 29, 2017
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trialJohn P Neoptolemos, Daniel H Palmer, Paula Ghaneh, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
BJS Open|May 22, 2026
Interhospital variations in practice and technical outcomes for endoscopic resection of early oesophagogastric adenocarcinoma: multicentre CONGRESS data set analysisKirsty Cole, Pradeep Bhandari, James A Gossage, et al.
Gut|March 29, 2024
National Institute for Health and Care Excellence (NICE) guidance on monitoring and management of Barrett's oesophagus and stage I oesophageal adenocarcinomaMassimiliano di Pietro, Nigel J Trudgill, Melina Vasileiou, et al.
European Journal of Cancer (Oxford, England : 1990)|March 25, 2017
NEOSCOPE: A randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinomaSomnath Mukherjee, Christopher Nicholas Hurt, Sarah Gwynne, et al.
BMC Cancer|April 17, 2015
NEOSCOPE: a randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinomaSomnath Mukherjee, Christopher N Hurt, Sarah Gwynne, et al.
Oncotarget|January 8, 2019
Genomic loss of heterozygosity and survival in the REAL3 trialElizabeth C Smyth, Catherine Cafferkey, Andrea Loehr, et al.
JAMA Oncology|June 21, 2019
Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma: A Randomized Phase 2 Clinical TrialElizabeth C Smyth, Samuel Rowley, Fay H Cafferty, et al.
The Lancet. Oncology|April 19, 2013
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trialTom Waddell, Ian Chau, David Cunningham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 5, 2024
Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III TrialDaniel H Palmer, Richard Jackson, Christoph Springfeld, et al.
Gut|November 17, 2020
EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancersElizabeth C Smyth, Georgios Vlachogiannis, Somaieh Hedayat, et al.
Lancet (London, England)|January 29, 2017
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trialJohn P Neoptolemos, Daniel H Palmer, Paula Ghaneh, et al.
Pageof 6